Adeka (4401) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
10 Mar, 2026Executive summary
Net sales for FY2024 1H rose 4.0% year-over-year to ¥195.0 billion, with operating profit up 23.6% to ¥18.2 billion and net profit attributable to owners up 8.9% to ¥11.4 billion.
The global economy showed gradual recovery, especially in emerging Asia, Europe, and the U.S., despite concerns over China and the Middle East.
Growth was driven by strong performance in chemicals, especially polymer additives, electronic, and environmental materials, while food products and life science segments saw declines.
The company revised its full-year forecast upward, projecting net sales of ¥426.0 billion and operating profit of ¥41.1 billion.
Financial highlights
Operating profit increased by ¥3.4 billion year-over-year, mainly due to higher sales volume, favorable exchange rates, and improved net pricing.
Gross profit increased from ¥47,289 million to ¥53,934 million year-over-year.
Ordinary profit rose 8.6% to ¥16,866 million, and basic earnings per share increased to ¥112.55 from ¥103.20.
Cash flows from operating activities improved to ¥33.0 billion, while cash and deposits decreased to ¥103.9 billion as of September 30, 2024.
Comprehensive income dropped to ¥8,956 million from ¥20,882 million due to negative foreign currency translation adjustments.
Outlook and guidance
Full-year net sales forecast revised to ¥426,000 million (up 6.6% year-over-year), with operating profit expected at ¥41,100 million (up 16.0%) and profit attributable to owners of parent at ¥24,500 million (up 6.6%).
Dividend forecast for FY2024 was raised to ¥97 per share, with a payout ratio of 40.3%.
Chemicals and life science segments are expected to drive growth in 2H, while food products face continued challenges.
Moderate but stable global economic growth is expected, with attention to U.S., China, and Middle East developments.
Latest events from Adeka
- Profit and sales rose, led by Life Science, with stable outlook and higher dividend forecast.4401
Q1 202610 Mar 2026 - Life Science strength drove profit growth, offsetting Chemicals and Food Products weakness.4401
Q2 202610 Mar 2026 - Profits and sales grew, led by Chemicals and Food Products, with raised outlook and Life Science loss.4401
Q1 202510 Mar 2026 - Strategic investments and innovation in semiconductor materials target rapid global growth.4401
Investor presentation10 Mar 2026 - 3Q FY2024 saw higher sales and profits, driven by Chemicals and global expansion.4401
Q3 202510 Mar 2026 - Record sales and profit growth driven by Chemicals, with continued expansion and higher dividends forecast.4401
Q4 202510 Mar 2026 - Profit rose on strong Life Science and Environmental Materials, offsetting Chemicals weakness.4401
Q3 202610 Mar 2026